21230-43-3 Usage
Uses
Used in Pharmaceutical Industry:
PYRAZOLE-4-CARBOXYLIC ACID, 3-AMINO-1-METHYL-, ETHYL ESTER is used as a key intermediate in the synthesis of various drugs and bioactive molecules for therapeutic applications. Its unique structure allows for the development of new drugs with potential anti-inflammatory and antitumor activities, contributing to the advancement of pharmaceutical research and drug discovery.
Used in Agrochemical Production:
PYRAZOLE-4-CARBOXYLIC ACID, 3-AMINO-1-METHYL-, ETHYL ESTER also serves as an intermediate in the production of agrochemicals, where it can be utilized in the synthesis of active ingredients for pesticides, herbicides, and other agricultural chemicals. Its involvement in agrochemical synthesis aids in the development of effective and targeted solutions for crop protection and management.
Used in Veterinary Drug Development:
PYRAZOLE-4-CARBOXYLIC ACID, 3-AMINO-1-METHYL-, ETHYL ESTER is employed in the veterinary industry as a building block for the development of drugs and pharmaceuticals for animal health. Its unique properties and reactivity make it suitable for the synthesis of veterinary drugs with potential applications in treating various diseases and conditions in animals.
Check Digit Verification of cas no
The CAS Registry Mumber 21230-43-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,1,2,3 and 0 respectively; the second part has 2 digits, 4 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 21230-43:
(7*2)+(6*1)+(5*2)+(4*3)+(3*0)+(2*4)+(1*3)=53
53 % 10 = 3
So 21230-43-3 is a valid CAS Registry Number.
InChI:InChI=1/C7H11N3O2/c1-3-12-7(11)5-4-10(2)9-6(5)8/h4H,3H2,1-2H3,(H2,8,9)
21230-43-3Relevant academic research and scientific papers
Substituted pyrazolopyrimidines
-
Page/Page column 89, (2008/06/13)
The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted heterobicyclic pyrimidines of Formula (I): wherein R1, R2, R3, R4, R5, X, W, and ring A are as defined herein; pharmaceutical compositions of substituted heterobicyclic pyrimidines of Formula (I); and their use in the treatment of chronic neurodegenerative diseases, neurotraumatic diseases, depression and/or diabetes. More particularly, the present invention relates to substituted pyrazolopyrimidines of Formula (I).
